Cargando…

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Mah, Michael, Febbraio, Mark, Turpin-Nolan, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353232/
https://www.ncbi.nlm.nih.gov/pubmed/34385976
http://dx.doi.org/10.3389/fendo.2021.684448
_version_ 1783736359286996992
author Mah, Michael
Febbraio, Mark
Turpin-Nolan, Sarah
author_facet Mah, Michael
Febbraio, Mark
Turpin-Nolan, Sarah
author_sort Mah, Michael
collection PubMed
description Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomarkers are implicated in metabolic disease and the circulating levels of these biomarkers are used in clinical settings to predict and monitor disease severity. There is convincing evidence that specific circulating ceramide species can be used as biological predictors and markers of cardiovascular disease, atherosclerosis and type 2 diabetes mellitus. Here, we review the existing literature that investigated sphingolipids as biomarkers for metabolic disease prediction. What are the advantages and disadvantages? Are circulating ceramides predominantly produced in the liver? Will hepatic sphingolipid inhibitors be able to completely prevent and treat metabolic disease? As sphingolipids are being employed as biomarkers and potential metabolic disease treatments, we explore what is currently known and what still needs to be discovered.
format Online
Article
Text
id pubmed-8353232
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83532322021-08-11 Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments? Mah, Michael Febbraio, Mark Turpin-Nolan, Sarah Front Endocrinol (Lausanne) Endocrinology Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomarkers are implicated in metabolic disease and the circulating levels of these biomarkers are used in clinical settings to predict and monitor disease severity. There is convincing evidence that specific circulating ceramide species can be used as biological predictors and markers of cardiovascular disease, atherosclerosis and type 2 diabetes mellitus. Here, we review the existing literature that investigated sphingolipids as biomarkers for metabolic disease prediction. What are the advantages and disadvantages? Are circulating ceramides predominantly produced in the liver? Will hepatic sphingolipid inhibitors be able to completely prevent and treat metabolic disease? As sphingolipids are being employed as biomarkers and potential metabolic disease treatments, we explore what is currently known and what still needs to be discovered. Frontiers Media S.A. 2021-07-27 /pmc/articles/PMC8353232/ /pubmed/34385976 http://dx.doi.org/10.3389/fendo.2021.684448 Text en Copyright © 2021 Mah, Febbraio and Turpin-Nolan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Mah, Michael
Febbraio, Mark
Turpin-Nolan, Sarah
Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title_full Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title_fullStr Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title_full_unstemmed Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title_short Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
title_sort circulating ceramides- are origins important for sphingolipid biomarkers and treatments?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353232/
https://www.ncbi.nlm.nih.gov/pubmed/34385976
http://dx.doi.org/10.3389/fendo.2021.684448
work_keys_str_mv AT mahmichael circulatingceramidesareoriginsimportantforsphingolipidbiomarkersandtreatments
AT febbraiomark circulatingceramidesareoriginsimportantforsphingolipidbiomarkersandtreatments
AT turpinnolansarah circulatingceramidesareoriginsimportantforsphingolipidbiomarkersandtreatments